Pluristem Receives Key Placental Cell Therapy Patent in Australia
Pluristem Therapeutics, Inc., a leading developer of placenta-based cell therapies, today announced it has been granted a new patent in Australia. Patent #2008300185, titled "Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced thereby for Therapy," covers the use of adherent placental cells for the treatment of ischemia, which is a restriction of blood supply to tissues, and for treatments of conditions requiring connective tissue repair or regeneration.
View full press release